Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Fludarabine and Treosulfan Conditioning Is Feasible and Leads to High OS and Low NRM

Chiara Bernardi, Stéphane Morisset, Amandine Pradier, Anne-Claire Mamez, Federica Giannotti, Sarah Morin, Stavroula Masouridi Levrat, Gabrielle Roth-Guepin, Maud D'Aveni, Céline Kicki, Arnaud Campidelli, Federico Simonetta, Simona Pagliuca, Yves Chalandon, Marie-Thérèse Rubio

Blood (2024) 144 (Supplement 1): 7301.

https://doi.org/10.1182/blood-2024-211435

Published: 2024

Journal Articles

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Blood (2024) 144 (Supplement 1): 478.

https://doi.org/10.1182/blood-2024-198903

Published: 2024

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Blood (2024) 144 (Supplement 1): 584.

https://doi.org/10.1182/blood-2024-194593

Published: 2024

Journal Articles

Long-Term Outcome of Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation (ASCT) - Impact of Therapeutic Strategy Following ASCT

Emilie Martin, Stéphane Morisset, Mohamad Sobh, Alfred Quillon, Hélène Boyer, Philippe Rey, Emmanuelle Nicolas-Virelizier, Amine Belhabri, Yann Guillermin, Laure Lebras, Valérie Mialou, Jean Paul Bourgeot, Melinda Teyssier, Anne-Sophie Michallet, Mauricette Michallet

Blood (2023) 142 (Supplement 1): 6682.

https://doi.org/10.1182/blood-2023-182700

Published: 2023

Journal Articles

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Blood (2023) 142 (Supplement 1): 1800.

https://doi.org/10.1182/blood-2023-173132

Published: 2023

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Blood (2023) 142 (Supplement 1): 3268.

https://doi.org/10.1182/blood-2023-173341

Published: 2023

Journal Articles

Impact of Residence in an Agricultural Zone on AML Characteristics

Vincent Marmouset, Berengere Gruson, Veronique Harrivel, Céline Berthon, Nicolas Duployez, Claude Preudhomme, Jean Pierre Marolleau, Pierre Morel, Carine Hauspie, Stéphane Morisset, Delphine Lebon

Blood (2023) 142 (Supplement 1): 2842.

https://doi.org/10.1182/blood-2023-173171

Published: 2023

Journal Articles

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Blood (2023) 142 (Supplement 1): 445.

https://doi.org/10.1182/blood-2023-181571

Published: 2023

Journal Articles

Spplaash Study: A Randomized Study to Evaluate the Incidence of Postdural Puncture Headache with the Use of Atraumatic Needles in Hematology

Yann Guillermin, Stéphane Morisset, Ugo Thévenet, Emmanuelle Nicolas-Virelizier, Anne-Sophie Michallet, Jerome Cornillon, Manon Sapet, Valentin Daguerre, Emmanuel Beillard, Denis Guyotat, Elisabeth Daguenet, Ludovic Fouillet

Blood (2023) 142 (Supplement 1): 129.

https://doi.org/10.1182/blood-2023-180601

Published: 2023

Journal Articles

Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure: A Report from the Residiag Study

Hippolyte Guerineau, Jean-Michel Cayuela, Stéphanie Dulucq, Violaine Tran Quang, Sihem Tarfi, Quentin Barathon, Corine Joy, Orianne Wagner-Ballon, Stéphane Morisset, Franck E. Nicolini, Lydia Roy, Sébastien Maury, Gabriel Etienne, Delphine Rea, Ivan Sloma

Blood (2023) 142 (Supplement 1): 4540.

https://doi.org/10.1182/blood-2023-186271

Published: 2023

Journal Articles

Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study

Franck E. Nicolini, Elisabetta Abruzzese, Gabrielle Roth-Guepin, Rami Abi-Tayeh, Vincent Alcazer, Sandrine Hayette, Stéphane Morisset, Françoise Huguet, Miriam Iezza, Fausto Castagnetti, Delphine Rea

Blood (2023) 142 (Supplement 1): 1799.

https://doi.org/10.1182/blood-2023-178326

Published: 2023

Journal Articles

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Blood (2022) 140 (Supplement 1): 7013–7015.

https://doi.org/10.1182/blood-2022-157963

Published: 2022

Journal Articles

A Genomic Approach in High-Grade B Cell Lymphoma with MYC and BCL2 and / or BCL6 Rearrangements: Two Clusters Stood out on Next Generation Sequencing Results

Arsène Vacherot, Emmanuel Beillard, Catherine Chassagne-Clément, Marie-Charlotte Laude, Pierre Sesques, Laure Lebras, Alexandra Traverse-Glehen, Claire Mauduit, Mauricette Michallet, Stéphane Morisset, Anne-Sophie Michallet, Yann Guillermin

Blood (2022) 140 (Supplement 1): 11878–11879.

https://doi.org/10.1182/blood-2022-169510

Published: 2022

Journal Articles

Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line, in Real-Life Conditions: Influence of Switching to Another TKI Prior to Cessation.

Franck E. Nicolini, Vincent Alcazer, Pascale Cony-Makhoul, Stéphanie Dulucq, Sandrine Hayette, Stéphane Morisset, Rachel Parat, Christophe Bouvier, Gabriel Etienne

Blood (2022) 140 (Supplement 1): 3918–3919.

https://doi.org/10.1182/blood-2022-163376

Published: 2022

Journal Articles

Standard Risk-Assessment of AML Doesn't Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy

Laura Simon, Alexis Caulier, Celine Berthon, Thomas Boyer, Véronique Harrivel, Magalie Joris, Amandine Charbonnier, Etienne Paubelle, Isabelle Leduc, Nicolas Duployez, Christophe Roumier, Claude Preudhomme, Stéphane Morisset, Jean-Pierre Marolleau, Delphine Lebon

Blood (2022) 140 (Supplement 1): 3225–3226.

https://doi.org/10.1182/blood-2022-164840

Published: 2022

Journal Articles

The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different

Franck E. Nicolini, Vincent Alcazer, Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Stephane Morisset, Christophe Bouvier, Francois-Xavier Mahon, Gabriel Etienne, Delphine Rea

Blood (2021) 138 (Supplement 1): 2552.

https://doi.org/10.1182/blood-2021-146722

Published: 2021

Journal Articles

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Blood (2021) 138 (Supplement 1): 2553.

https://doi.org/10.1182/blood-2021-146412

Published: 2021

Journal Articles

Post-Transplantation Cyclophosphamide for Gvhd Prophylaxis in Related and Unrelated Allogeneic Hematopoietic Cell Transplantation: Study from the SFGM-TC Registry

Blood (2021) 138 (Supplement 1): 2883.

https://doi.org/10.1182/blood-2021-151989

Published: 2021

Journal Articles

Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers

Blood (2021) 138 (Supplement 1): 4379.

https://doi.org/10.1182/blood-2021-148678

Published: 2021

Journal Articles

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Franck E Nicolini, MDPhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD, Stephanie Dulucq, PharmD, PhD, Sandrine Hayette, PhD, Stephane Morisset, BioStat, Jean-Michel Cayuela, PharmD, PhD, Marie-Pierre Fort, PhD, Christophe Bouvier, CRA, Clemence Deteix-Santana, MD, Etienne Lengline, MD, Delphine Rea, MDPhD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139921

Published: 2020

NARROW

Fludarabine and Treosulfan Conditioning Is Feasible and Leads to High OS and Low NRM

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Long-Term Outcome of Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation (ASCT) - Impact of Therapeutic Strategy Following ASCT

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Impact of Residence in an Agricultural Zone on AML Characteristics

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Spplaash Study: A Randomized Study to Evaluate the Incidence of Postdural Puncture Headache with the Use of Atraumatic Needles in Hematology

Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure: A Report from the Residiag Study

Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

A Genomic Approach in High-Grade B Cell Lymphoma with MYC and BCL2 and / or BCL6 Rearrangements: Two Clusters Stood out on Next Generation Sequencing Results

Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line, in Real-Life Conditions: Influence of Switching to Another TKI Prior to Cessation.

Standard Risk-Assessment of AML Doesn't Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy

The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Post-Transplantation Cyclophosphamide for Gvhd Prophylaxis in Related and Unrelated Allogeneic Hematopoietic Cell Transplantation: Study from the SFGM-TC Registry

Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only